Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRM-201 (Rofecoxib) in Hemophilic Arthropathy
NCT04684511Phase 3Terminated
- Sponsor
- Tremeau Pharmaceuticals
- Start
- Jun 2021
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of rofecoxib in hemophilic arthropathy (HA), sponsored by Tremeau Pharmaceuticals. Started Jun 2021; status: terminated.
02
Drugs
rofecoxib
03
Conditions
hemophilic arthropathy (HA)
Beyond the preview
Go deeper on NCT04684511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04684511.